Cancer cells fueled by the mutant KRAS oncogene, which makes them notoriously difficult to treat, can be killed by blocking a more vulnerable genetic partner of KRAS, scientists report. By targeting the second, more easily inhibited “co-dependent” gene, TBK, the strategy bypasses the so far unfruitful head-on assault against the highly resistant KRAS gene.